ORR,PFS,DoR Individual Responses Prior ALK TKI CNS Efficacy
Guidelines ALK Resistance Mutations
LORVIQUA® demonstrates efficacy in patients previously treated with 2nd-generation ALK TKls2
Individual responses in the primary analysis of the LORVIQUA® registrational study2
1 prior 2nd-generation ALK TKI*± CT (EXP3B) (n=28)2
Adapted from Solomon BJ, et al. 2018.*
≥2 prior ALK TKIs* ± CT (EXP4-5) (n=111)2
Adapted from Solomon BJ,et al. 2018.*
Data cutoff: March 15, 2017.2
*Patients predominantly received either alectinib or ceritinib as the last ALK TKI ± CT before LORVIQUA. Each bar shows an individual patient's maximum reduction in target lesion size (assessed by ICR). Colors show the patients' best overall responses per RECIST version 1.1 by ICR. Patients withat least one on-study target lesion assessment were included. If a procedure differed (and was not interchangeable) from the procedure at screening, the percent change from baseline could not be calculated and is not displayed.2
† Complete response was defined as the disappearance of all target lesions. When nodal disease was included in target lesions, reversion to normal node size (<10 mm) prevented the percent change from baseline from reaching 100%. Some patients with a total change from baseline of 100% are shown as partial responses due to the inclusion of non-target lesions in the summary.2
For Healthcare Professionals only
Abbreviations : ALK+, Anaplastic lymphoma kinase positive; CNS, central nervous system; CT, chemotherapy; DoR, duration of response; ICR, independent central review; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PFS, progression· free survival; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.
1. Pfizer. LORVIQUA® (lorlatinib) Prescribing Information, Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12540 Accessed September 23,2021.
2. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654-1667.
The use of lorlatinib has been associated with increases in serum cholesterol and triglycerides. Serum cholesterol and triglycerides should be monitored before the initiation of lorlatinib; 2, 4, and 8 weeks after initiating lorlatinib, and periodically thereafter. Initiation, or increase in the dose, of lipid-lowering agents is required.
Central nervous system (CNS) effects have been observed in patients receiving lorlatinib including seizures, psychotic effects, changes in cognitive function, mood (including suicidal ideation), mental status, sleep, and speech. Dose modification or discontinuation may be required for those patients who develop CNS effects.
PR interval prolongation and atrioventricular (AV) block events have been reported in patients receiving lorlatinib. Monitor electrocardiogram (ECG) prior to initiating lorlatinib and monthly thereafter, particularly in patients with predisposing conditions to the occurrence of clinically significant cardiac events. Dose modification may be required for those patients who develop AV block.
Elevations of lipase and/or amylase have occurred in patients receiving lorlatinib. Median time of occurrence of increase in serum lipase and amylase is 70 days (range: 7 days to 696 days) and 41 days (range: 7 days to 489 days), respectively. Risk of pancreatitis should be considered in patients receiving lorlatinib due to concomitant hypertriglyceridemia and/or a potential intrinsic mechanism. Patients should be monitored for lipase and amylase elevations prior to the start of lorlatinib treatment and regularly thereafter as clinically indicated.
Severe or life threatening pulmonary adverse drug reactions consistent with ILD/pneumonitis have occurred with lorlatinib. Any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough and fever) should be promptly evaluated for ILD/pneumonitis. Lorlatinib should be withheld and/or permanently discontinued based on severity.
Hypertension has been reported in patients receiving lorlatinib. Blood pressure should be controlled prior to the initiation of lorlatinib. Blood pressure should be monitored after 2 weeks and at least monthly thereafter during treatment with lorlatinib. Lorlatinib should be withheld and resumed at a reduced dose or permanently discontinued based on severity.
Hyperglycemia has occurred in patients receiving lorlatinib. Fasting serum glucose should be assessed prior to the initiation of lorlatinib and monitored periodically thereafter. Lorlatinib should be withheld and resumed at a reduced dose or permanently discontinued based on severity.
Concomitant use of any strong CYP3A inducer is contraindicated. Any strong CYP3A inducers have to be discontinued for at least 3 plasma half-lives of the strong CYP3A inducer before lorlatinib treatment is started. No clinically meaningful changes in liver function tests were seen in healthy subjects after receiving a combination of lorlatinib with the moderate CYP3A inducer modafinil.
Women of childbearing potential should be advised to avoid getting pregnant while receiving lorlatinib. Male fertility may be compromised during treatment with lorlatinib. Men should seek advice on effective fertility preservation before treatment.